Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, with a growing healthcare burden due to an aging population and continued exposure to risk factors. To make matters worse, there are no drugs available that can modify the disease progression/burden of disease/rate of decline in lung function.

Now, a new potential avenue has emerged for combating COPD as Nordic Bioscience secured access to ECLIPSE, a highly relevant cohort of samples and clinical data—presenting an opportunity for potential pharmaceutical partners to leverage the right biomarker technologies.

Please don't hesitate to contact us if you have any questions or other inquiries.

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.